Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS)
约翰·霍普金斯大学 SARS-CoV-2 发病机制和免疫卓越中心 (JH-EPICS)
基本信息
- 批准号:10706725
- 负责人:
- 金额:$ 11.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAddressAffectAgeAntibodiesAntibody ResponseAntibody-mediated protectionAntigensBasic ScienceBiometryCOVID-19COVID-19 patientCOVID-19 severityCell surfaceCellsCessation of lifeClinicalClinical SciencesCollaborationsCommunicable DiseasesComplementComplexCoupledData AnalysesDevelopmentDiabetes MellitusDiseaseEnsureEnzyme-Linked Immunosorbent AssayEpidemiologic MonitoringEpidemiologyEthnic OriginEvaluationFlow CytometryFoundationsGenderGoalsHIVHealthHealthcare SystemsHeart DiseasesHumanImmuneImmune responseImmunityImmunoglobulin Class SwitchingImmunologyImmunomodulatorsInfantInfectionInflammasomeInflammatory ResponseInfrastructureInterdisciplinary StudyInternationalLeadershipMediatingMetabolicMethodsMissionModelingMonoclonal Antibody TherapyMyeloid-derived suppressor cellsOutcomePathogenesisPathologicPathologyPatientsPeripheral Blood Mononuclear CellPersonsPopulationProspective cohortProteinsProtocols documentationPublic HealthRaceReagentRegimenReportingResearchResearch ActivityResearch PersonnelResearch Project GrantsResourcesRespiratory Tract InfectionsRiskSARS-CoV-2 antibodySARS-CoV-2 immune responseSARS-CoV-2 immunitySARS-CoV-2 infectionSamplingScienceSerologySerology testSeverity of illnessSex DifferencesSolidStainsStatistical Data InterpretationStatistical ModelsSurrogate MarkersSymptomsT-LymphocyteTestingTherapeuticTrainingTranslational ResearchUrsidae FamilyVaccine DesignViralViral PathogenesisVirusage differenceantibody-dependent cell cytotoxicitybasebiosafety level 3 facilitycomorbidityexperimental studygender differenceinnate immune sensinginsightintersectionalitymaleneutralizing antibodynew therapeutic targetnovelnovel markerorgan transplant recipientpandemic diseaseracial differencerational designresponsesample fixationsevere COVID-19sexsingle cell analysistherapeutic evaluationtherapy developmentvaccine candidatevaccine developmentvaccine evaluationvirology
项目摘要
Johns Hopkins has broad expertise in the science of human health, with viral immunity, pathogenesis, epidemiology, biostatistics, and surveillance emerging as integral components of the multidisciplinary research mounted at Johns Hopkins during the current pandemic. We have operated a Serological Sciences Center of Excellence: the Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS). The overarching goal of JH-EPICS since 2020 with ongoing projects to distinguish immune responses that protect from those that cause pathology during infection and to analyze vaccine induced immune responses. We have resources and samples available to systematically evaluate innate, T cell, and antibody responses to SARS-CoV-2 in peripheral blood mononuclear cells and serological samples from COVID-19 vaccine recipients and patients sampled longitudinally. JH-EPICS contains three interconnecting Research Projects (RPs). RP1 focuses on innate immune sensing and activation of the human inflammasome by SARS-CoV-2, with evaluation of how anti-SARS-CoV-2 antibodies modulate innate sensing. RP2 uses traditional techniques to assess T cell responses, including ELISpot, and a novel flow-cytometry based platform that enables single cell analysis of cell surface markers combined with intracellular staining for proteins involved in metabolic programming. In RP3, the magnitude, duration, and class switching of SARS-CoV-2-specific antibody isotypes as well as virus-specific neutralizing antibody responses is analyzed and compared with non-neutralizing antibody functions, e.g., complement fixation and antibody-dependent cellular cytotoxicity, using a novel core set of serological assays. A centralized Virology Reagent Core provides antigen for ELISAs, reagents to identify virus-specific immune cell populations, inactivated SARS-CoV-2 viruses, methods for quantifying SARS-CoV-2, and access to biosafety level 3 facilities and training needed to perform any experiments involving live SARS-CoV-2. The Analysis Resource Core provides statistical modeling and analysis to frame and test hypotheses about the mechanisms mediating the severity of COVID-19 as well as the intersectionality of sex, gender, age, and racial differences in immune mechanisms of COVID-19 disease and vaccination. In concert with the trans-network collaborations, this research provides significant insights into pathologic immune responses to SARS-CoV-2 and elucidates mechanisms of immunity against SARS-CoV-2 infection and vaccination. By uncovering the correlates of protective immunity following boosting, JH-EPICS research will further enhance vaccine design and evaluation of vaccine candidates.
约翰霍普金斯大学在人类健康科学方面拥有广泛的专业知识,病毒免疫、发病机制、流行病学、生物统计学和监测是当前大流行期间约翰霍普金斯大学开展的多学科研究的组成部分。我们运营了一个血清学科学卓越中心:约翰霍普金斯SARS-CoV-2发病机制和免疫卓越中心(JH-EPICS)。自2020年以来,JH-EPICS的总体目标是通过正在进行的项目来区分免疫反应,这些免疫反应可以保护感染期间引起病理学的免疫反应,并分析疫苗诱导的免疫反应。我们有资源和样本可用于系统地评估外周血单核细胞和血清学样本中SARS-CoV-2的先天性、T细胞和抗体反应,这些样本来自COVID-19疫苗接种者和纵向采样的患者。JH-EPICS包含三个相互关联的研究项目(RP)。RP 1主要研究SARS-CoV-2对人类炎性小体的先天免疫感知和激活,并评估抗SARS-CoV-2抗体如何调节先天免疫感知。RP 2使用传统技术来评估T细胞反应,包括ELISpot和一种新型的基于流式细胞术的平台,该平台能够对细胞表面标志物进行单细胞分析,并结合细胞内染色来检测参与代谢编程的蛋白质。在RP 3中,分析了SARS-CoV-2特异性抗体同种型以及病毒特异性中和抗体应答的幅度、持续时间和类别转换,并与非中和抗体功能进行比较,例如,补体结合和抗体依赖性细胞毒性,使用一套新的核心血清学试验。一个集中的病毒学试剂核心提供ELISA的抗原,用于识别病毒特异性免疫细胞群的试剂,灭活的SARS-CoV-2病毒,定量SARS-CoV-2的方法,以及进行任何涉及活SARS-CoV-2的实验所需的生物安全3级设施和培训。分析资源核心提供统计建模和分析,以构建和检验有关COVID-19严重程度介导机制的假设,以及COVID-19疾病和疫苗接种免疫机制中性别、性别、年龄和种族差异的交叉性。与跨网络合作一致,这项研究为SARS-CoV-2的病理免疫反应提供了重要的见解,并阐明了SARS-CoV-2感染和疫苗接种的免疫机制。通过揭示加强免疫后保护性免疫的相关性,JH-EPICS研究将进一步加强疫苗设计和候选疫苗的评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREA L COX其他文献
ANDREA L COX的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREA L COX', 18)}}的其他基金
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10614971 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10205729 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10205731 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10398149 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Immunologic and Metabolic Profiles of T cells that control diverse HCV infections
控制多种 HCV 感染的 T 细胞的免疫学和代谢特征
- 批准号:
10398150 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Sex, obesity, immunometabolism, and viral persistence in post-acute sequelae of SARS-CoV-2 infection
SARS-CoV-2 感染急性后遗症中的性别、肥胖、免疫代谢和病毒持续性
- 批准号:
10554731 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10398147 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10398148 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10671902 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Research Grant